Genmab A/S (GMAB) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Genmab A/S (NASDAQ: GMAB) recently:

• 4/30/2026 – Genmab A/S had its price target lowered by HC Wainwright from $40.00 to $38.00. They now have a “buy” rating on the stock.
• 4/27/2026 – Genmab A/S was upgraded by Truist Financial Corporation to “strong-buy”.
• 4/22/2026 – Genmab A/S was upgraded by BNP Paribas Exane from “hold” to “strong-buy”.
• 4/22/2026 – Genmab A/S was upgraded by The Goldman Sachs Group, Inc. from “neutral” to “buy”.
• 3/27/2026 – Genmab A/S is now covered by Wolfe Research. They set an “outperform” rating and a $32.00 price target on the stock.
• 3/25/2026 – Genmab A/S was upgraded by Truist Financial Corporation to “strong-buy”.

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.